1Garza L,Aude YW,Saucedo JF.Can we preventin-stent restenosis[J].Curr Opin Cardiol,2002,17(5):518-525.
2Kornowski R,Hong MK,Tio FO,et al.In-stent restenosis:contributions of inflammatory response and arterial injury to neointimal hyperplasia[J].J Am Coll Cardiol,1998,31(1):224-230.
3Mehran R,Dangas G,Abizzaid AS,et al.Angiographic patterns of in-stent restenosis:classification and implications for long-term outcome[J].Circulation,1999,100(18):1872-1878.
4Speidel CM,Eisenberg PR,Ruf W,et al.Tissue factor mediates prolonged procoagulant activity on the luminal surface of balloon-injured aortas in rabbits[J].Circulation,1995,92 (11):3323-3330.
5Glover C,Ma X,Chen YX,et al.Human in-stent restenosis tissue obtained by means of coronary atherectomy consists of an abundant proteoglycan matrix with a paucity of cell proliferation[J].Am Heat J,2002,144(4):702-709.
6Kasaoko S,Tobis JM,Akiyarna T,et al.Angiography and intravascular ultrasound predictors of in-stent restenosis[J].J Am Coll Cardiol,1998,32(6):1630-1635.
7Sahara M,Kirigaya H,Oikawa Y,et al.Arterial remodeling patterns before intervention predict diffuse in-stent restenosis:an intravascular ultrasound study[J].J Am Coll Cardiol,2003,42(10):1731-1738.
8Niroomand F,Heauer O,Tiefenbacher C,et al.Influence of alcohol consumption on restenosis rate after percutaneous transluminal coronary angioplasty and stent implation[J].Heart,2004,90(10):1189-1193.
3Bennett MR. In-stent stenosis:Pathology and implications for the development of drug e luting stents [ J ]. Circulation, 2003,89 ( 2 ) : 218-224.
4Lowe HC, Mino M, Mark E J, etal. Histopathology of coronary in-stent restenosis following gamma brachytherapy[ J ]. Heart,2003,89 (1) : 11-13.
5Virmani R,Kolodgie FD,Farb A,etal. Drug eluting stents:are human and animal studies comparable [ J ]. Heart,2003,89 ( 2 ) : 133- 138.
6Eduardo S, Marco AC, Alexandre CA, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up [ J ]. Circulation, 2001,104 ( 17 ) :2007- 2011.
7Kahan BD ,Wong RL,Carter C ,et al. A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent eyclosporine prednisone treated renal transplant recipients [ J ]. Transplantation, 1999,68 ( 8 ) : 1100- 1106.
8Yatscoff RW, Wang P, Chan K, et al. rapaamycin : distribution, pharmacokinetics and therapaeuticc range investingations[ J]. Ther DrugMonit, 1995,17(6) :666-671.
9Augoustides JG, Riha H. Recent progress in heart failure treatment and heart transplantation[ J]. J Cardiothorac Vasc A nesth,2009,23 (5) :738-748.
10White DA, Schwartz LH, Dimitrijevic S, et al. Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus ( RAD001 ) [ J ]. J Thorac Oncol, 2009,4 (11) :1357-1363.
